Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3401-3420 of 3,900 trials

Atorvastatin for Patients with Chronic Myeloproliferative Neoplasms

We are studying whether atorvastatin can improve health markers in patients with specific blood disorders. This trial looks at its effects alongside standard treatments to see how it may help manage symptoms and disease progression.

Blood Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInternal Medicine

Polymyalgia Rheumatica: Hydrocortisone Supplement Study

We are investigating whether supplemental hydrocortisone helps improve quality of life for patients with polymyalgia rheumatica or giant cell arteritis experiencing adrenal insufficiency. The focus is on how it affects fatigue during stress.

Glucocorticoid Induced Adrenal Insufficiency6-12 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyRheumatology

Lung Cancer: JNJ-90301900 with Chemoradiation

We are studying a new drug combined with standard treatments for patients with advanced non-small cell lung cancer. The goal is to see if this combination improves treatment response.

Locally Advanced Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Multiple Sclerosis: CBD for Sleep Quality

We are investigating whether cannabidiol (CBD) can improve sleep quality in patients with multiple sclerosis. This study aims to help those struggling with sleep issues related to their condition.

Insomnia3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Lung Health: Avalyn Inhaled Antifibrotic Study

We are studying the long-term safety and effects of Avalyn's inhaled antifibrotic medications on lung function in patients who have previously participated in related trials.

Pulmonary FibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePulmonology

Type 2B von Willebrand Disease: BT200 Treatment Study

We are testing a new treatment called BT200 for people with Type 2B von Willebrand disease. The goal is to see if it improves blood clotting and is safe for use.

Von Willebrand's Disease Type 2B≤3 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesHematology

Crohn’s Disease: Tulisokibart Treatment Study

We are testing a new medication, tulisokibart, for people with moderately to severely active Crohn’s disease. The goal is to see if it helps achieve remission and improve symptoms compared to a placebo.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Hepatocellular Carcinoma: IMA970A and Durvalumab

We are testing a new treatment combination for patients with early-stage liver cancer after standard therapies. This study aims to see if it can improve treatment results.

Early Stage Liver Cancer>2 yearsSafety phase (I)HepatologyOncology

Cirrhosis: Carvedilol for Preventing Digestive Bleeding

We are studying whether Carvedilol can help prevent digestive bleeding in patients with cirrhosis. The trial measures its effects on liver pressure and overall tolerance over three months.

Cirrhotic Portal Hypertension3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Fecal Microbiota Transplantation: KF2022#1 Trial

We are investigating how fecal microbiota transplantation may affect enzyme activities in the body. This study aims to understand its potential benefits for patients with certain health conditions.

Irritable Bowel SyndromeClostridioides difficile Infection>2 yearsSafety phase (I)GastroenterologyInternal Medicine

Uncontrolled Asthma: GSK5784283 Treatment Study

We are testing a new antibody treatment for adults with uncontrolled asthma to see if it helps improve lung function and asthma control compared to a placebo.

Asthma1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPulmonology

Advanced GEP-NET: [177Lu]Lu-DOTA-TATE Treatment Study

We are testing a new treatment combining [177Lu]Lu-DOTA-TATE and octreotide LAR for patients with advanced Grade 1 and Grade 2 GEP-NET. The goal is to see if it can better delay disease progression and improve quality of life compared to existing therapies.

Gastroenteropancreatic Neuroendocrine Tumors1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Idiopathic Pulmonary Fibrosis: CAL101 Treatment Study

We are studying whether CAL101 can improve lung function in patients with idiopathic pulmonary fibrosis compared to a placebo. The trial also looks at the safety of this new treatment.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Transthyretin Amyloidosis with Cardiomyopathy: Vutrisiran Study

We are evaluating the safety and effectiveness of vutrisiran in patients with transthyretin amyloidosis and heart issues. This study includes those continuing treatment or switching from another medication.

Cardiac Amyloidosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Fertility Study: Metformin for Women Post-Thyroid Cancer

We are evaluating whether metformin can improve fertility in women treated with radioactive iodine for thyroid cancer. The study will look at hormone levels and ovarian health to see how effective the treatment is.

Papillary Thyroid Carcinoma1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesGynecology and ObstetricsOncology

Esophageal Cancer: Tislelizumab for Elderly Patients

We are studying Tislelizumab to see if it helps elderly patients with advanced esophageal cancer who cannot receive chemotherapy. The trial aims to assess survival rates and quality of life improvements.

Esophageal Squamous Cell Carcinoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: L-Annamycin with Cytarabine

We are studying a new treatment combining L-Annamycin with Cytarabine for adults with difficult-to-treat acute myeloid leukemia. The goal is to see if this combination can help achieve remission better than a placebo.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncology

HER2-Positive Metastatic Breast Cancer: [177Lu]Lu-ABY-271 Treatment

We are studying a new treatment to see if it is safe and how it distributes in the body for patients with HER2-positive metastatic breast cancer. This trial will help us understand its effects on tumors and normal organs.

HER2-positive Metastatic Breast Cancer3-6 monthsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Recurrent Solid Cancer: PEP-010 Treatment Study

We are testing a new peptide drug, PEP-010, for patients with recurrent or metastatic solid cancers. The study will evaluate its safety and how well it works alone and with other chemotherapy drugs.

Recurrent and Metastatic Solid CancerSafety phase (I)Oncology

Chronic Inflammatory Demyelinating Polyneuropathy: Batoclimab Study

We are studying the long-term safety and tolerability of batoclimab in adults with CIDP. This trial aims to see how well the medication works for managing symptoms over time.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology